-
-
SHOP
HPV E6/E7: A Key Biomarker in Cancer Diagnosis
2025-08-30Introduction
Human papillomavirus (HPV) is one of the most critical oncogenic viruses, responsible for more than 90% of cervical squamous cell carcinomas and a significant proportion of head and neck cancers. While HPV DNA detection is common, it does not always reflect whether the infection is biologically active. This is where HPV E6/E7 mRNA detection becomes essential.
At Celnovte Biotech, we developed highly sensitive E6/E7 mRNA in situ hybridization probes that bring precision and clarity to HPV-related cancer diagnostics, helping pathologists, clinicians, and hospital partners make more accurate decisions.
Why E6/E7 Matters
- Core oncogenes of HPV:
- Direct evidence of viral activity:
- Prognostic value:
Simply put: E6/E7 is the most clinically meaningful biomarker of HPV-driven cancer.
Challenges with Traditional Markers
- p16 immunohistochemistry (IHC) is widely used but not fully reliable:
- HPV DNA PCR or ISH confirms infection but cannot tell if the virus is transcriptionally active.
This creates uncertainty in diagnosis, prognosis, and treatment planning.
Why Celnovte’s E6/E7 Probes Stand Out
🔹 High Sensitivity & Specificity
- Multiple studies demonstrate that HPV E6/E7 mRNA ISH outperforms p16 and HPV DNA tests in detecting clinically relevant infection .
🔹 Accurate Differentiation
- Distinguishes HPV-related adenocarcinoma vs. non-HPV adenocarcinoma with superior diagnostic accuracy (sensitivity ~76%, specificity ~80%) .
🔹 Better Prognostic Stratification
- Clearer correlation with CIN progression, HSIL risk, and survival outcomes in head & neck cancers .
🔹 Clinical Utility Across Tumors
- Proven application in cervical, oropharyngeal, vulvar, and anal cancers, making it a versatile diagnostic tool.
Clinical Impact for Hospitals and Partners
- For Pathologists: Provides clarity in ambiguous cases where morphology or p16 results are inconclusive.
- For Oncologists: Enables more accurate risk stratification and prognosis prediction.
- For Hospitals: Enhances diagnostic confidence, reduces misclassification, and improves patient management.
- For Global Partners: Publications featuring Celnovte’s E6/E7 probes provide strong academic endorsement, supporting hospital adoption worldwide.
Conclusion
HPV-related cancers remain a global challenge — but detecting transcriptionally active HPV is the key to accurate diagnosis and prognosis.
Celnovte’s E6/E7 mRNA probes deliver that precision, making them the preferred solution for clinicians and pathologists aiming for reliable, high-quality cancer diagnostics.
🌍 With increasing recognition in peer-reviewed publications, our technology is set to help hospitals and partners worldwide bring better clarity, better care, and better outcomes to patients.
👉 Interested in learning how E6/E7 probes can strengthen your pathology practice? Connect with us here on LinkedIn.
Related News
